Quarterly ResultMay 14, 2026, 04:42 PM
Valion Bio Q1 Net Loss $6.2M; Completes Corporate Transformation
AI Summary
Valion Bio (formerly Tivic Health Systems, Inc.) reported a net loss of $6.2 million for Q1 2026, compared to $1.5 million in Q1 2025. Operating expenses increased to $5.6 million from $1.4 million, primarily due to the acquisition of Velocity Bioworks and corporate rebranding costs. The company completed its corporate transformation, changing its name to Valion Bio, Inc. and ticker to VBIO, while advancing its Entolimod platform, increasing government engagement, and integrating its CDMO subsidiary, Velocity Bioworks.
Key Highlights
- Completed corporate transformation: Tivic Health Systems, Inc. to Valion Bio, Inc. (TIVC to VBIO).
- Q1 2026 net loss: $6.2 million, compared to $1.5 million in Q1 2025.
- Q1 2026 operating expenses: $5.6 million, up from $1.4 million in Q1 2025.
- Cash and cash equivalents: $7.2 million at March 31, 2026, down from $12.6 million at Dec 31, 2025.
- Advanced Entolimod platform for Acute Radiation Syndrome (ARS) with U.S. government agencies.
- Continued integration of Velocity Bioworks, CDMO subsidiary acquired in December 2025.
- Advanced Entolasta, next-generation TLR5 agonist for oncology supportive care.